Takuhisa Nukaya

Toyoake, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.

Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: June 15, 2026

Timing-dependent skin toxicity phenotypes during enfortumab vedotin plus pembrolizumab therapy for advanced urothelial carcinoma.

Timing-dependent skin toxicity phenotypes during enfortumab vedotin plus pembrolizumab therapy for advanced urothelial carcinoma.

Journal: International journal of clinical oncology

Published: June 04, 2026

Enfortumab vedotin plus pembrolizumab for recurrent metastatic urothelial carcinoma following adjuvant nivolumab.

Enfortumab vedotin plus pembrolizumab for recurrent metastatic urothelial carcinoma following adjuvant nivolumab.

Journal: Japanese journal of clinical oncology

Published: May 25, 2026

Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study.

Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study.

Journal: International journal of clinical oncology

Published: April 11, 2026

Development of a Prognostic Model for Patients Aged ≤65 Years With Metastatic Renal Cell Carcinoma.

Development of a Prognostic Model for Patients Aged ≤65 Years With Metastatic Renal Cell Carcinoma.

Journal: Anticancer research

Published: April 02, 2026

Efficacy and safety of first-line immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients on hemodialysis.

Efficacy and safety of first-line immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients on hemodialysis.

Journal: Urologic oncology

Published: April 02, 2026

Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter Japanese cohort study.

Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter Japanese cohort study.

Journal: Urologic oncology

Published: March 30, 2026

Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy.

Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy.

Journal: Japanese journal of clinical oncology

Published: March 16, 2026

Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study.

Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 24, 2026

Incidence and Risk Factors for Perioperative Infections After Robot-Assisted Radical Prostatectomy: A Multicenter Study.

Incidence and Risk Factors for Perioperative Infections After Robot-Assisted Radical Prostatectomy: A Multicenter Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 26, 2026

First-Line Therapy for Advanced Renal Cell Carcinoma: Score-Matched Analysis of Dual Combination Immunotherapy versus Combination of Tyrosine Kinase Inhibitors and Immunotherapy in the TOURS Multicenter Study.

First-Line Therapy for Advanced Renal Cell Carcinoma: Score-Matched Analysis of Dual Combination Immunotherapy versus Combination of Tyrosine Kinase Inhibitors and Immunotherapy in the TOURS Multicenter Study.

Journal: Targeted oncology

Published: December 28, 2025

Feasibility and Early Outcomes of Single-Port Robot-Assisted Partial Nephrectomy via Supine Low Anterior Access.

Feasibility and Early Outcomes of Single-Port Robot-Assisted Partial Nephrectomy via Supine Low Anterior Access.

Journal: Asian journal of endoscopic surgery

Published: November 05, 2025

Showing 1-12 of 57

Last Updated: 09/26/2026